We are live on ! Find out more
CCEL icon

Cryo-Cell International

14 hedge funds and large institutions have $10.1M invested in Cryo-Cell International in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more funds holding

Funds holding: 1014 (+4)

29% more capital invested

Capital invested by funds: $7.88M → $10.1M (+$2.25M)

2.89% more ownership

Funds ownership: 7.7%10.59% (+2.9%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
14
Holders Change
+4
Holders Change %
+40%
% of All Funds
0.22%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
3
Reduced
4
Closed
Calls
Puts
Net Calls
Net Calls Change

CCEL Hedge Fund Activity: Q4 2021 in Review

14 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cryo-Cell International (CCEL) for Q4 2021, worth a combined $10.1M — up 29% from $7.88M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CCEL positions and 0 closed out — a net gain of 4 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $901K. The largest seller was ISZO Capital Management, cutting an estimated $169K.

  • 14 institutional investors held Cryo-Cell International (CCEL) as of Q4 2021, up from 10 in Q3 2021.
  • Funds reported $10.1M of Cryo-Cell International stock for Q4 2021, up 29% quarter-over-quarter.
  • 4 funds opened new Cryo-Cell International positions in Q4 2021 and 0 closed out, a net change of +4 holders.
  • The largest Cryo-Cell International buyer in Q4 2021 was Vanguard Group, an estimated $901K added.
  • The largest Cryo-Cell International seller in Q4 2021 was ISZO Capital Management, an estimated $169K sold.

Based on aggregated 13F filings for Q4 2021.